CRISPR Therapeutics AG
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CRSP in the last 30 days.
See all $CRSP insider activity →CRISPR Therapeutics (CRSP) presented one-year data from its Phase 1a trial of CTX310, showing significant reductions in ANGPTL3, triglycerides, and LDL. The therapy was well-tolerated. The company is advancing to Phase 1b, with an update expected in 2026.
Citizens reiterated a Market Outperform rating and $80 price target for CRISPR Therapeutics (CRSP), citing upcoming gene therapy data and potential 40% upside. The firm highlighted the company's focus on severe hypertriglyceridemia and refractory hypercholesterolemia, with a one-time therapy approach. CRISPR's label expansion for CASGEVY and Vertex Pharmaceuticals' promising data also support the positive outlook, according to Citizens.
Simply Wall St reports CRISPR Therapeutics (CRSP) drew renewed attention after it posted Q2 2026 results on Aug. 3. The company reported revenue of $10.18M and a reduced net loss of $91.15M. The stock rose 3.64% in one day and 11.52% over a week. A DCF model estimates fair value at $218.96 versus a $53.52 close.
Over the past 7 days, alphai's AI scored 3 news stories mentioning CRSP (CRISPR Therapeutics AG). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent CRSP coverage spans earnings, financial news and sector analysis.
Positive trial data may boost CRSP stock and validate its gene‑editing platform.
Analyst reaffirmation may support modest upside but no immediate catalyst.
The article frames CRSP’s earnings as a near-term momentum catalyst while highlighting valuation uncertainty versus a DCF fair value.
Beat on revenue and improved loss, alongside strong Casgevy commercial momentum and a large cash balance, supports a near-term sentiment tailwind.
The quarter’s loss magnitude and CASGEVY revenue trajectory are the core near-term fundamentals for CRSP, shaping expectations for cash burn and commercialization momentum.
alphai scores every news story that mentions CRSP with an AI model for sentiment and relevance, and aggregates insider trades from CRISPR Therapeutics AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
CRISPR Therapeutics (CRSP) presented one-year data from its Phase 1a trial of CTX310, showing significant reductions in ANGPTL3, triglycerides, and LDL. The therapy was well-tolerated. The company is advancing to Phase 1b, with an update expected in 2026.
2 min readCitizens reiterated a Market Outperform rating and $80 price target for CRISPR Therapeutics (CRSP), citing upcoming gene therapy data and potential 40% upside. The firm highlighted the company's focus on severe hypertriglyceridemia and refractory hypercholesterolemia, with a one-time therapy approach. CRISPR's label expansion for CASGEVY and Vertex Pharmaceuticals' promising data also support the positive outlook, according to Citizens.
1 min readSimply Wall St reports CRISPR Therapeutics (CRSP) drew renewed attention after it posted Q2 2026 results on Aug. 3. The company reported revenue of $10.18M and a reduced net loss of $91.15M. The stock rose 3.64% in one day and 11.52% over a week. A DCF model estimates fair value at $218.96 versus a $53.52 close.
6 min readCRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.
6 min readCRISPR Therapeutics (CRSP) reported Q2 2026 total revenue of $10.2M and a net loss of $91.2M for the quarter ended June 30. Cash, cash equivalents and marketable securities were $2.36B vs $1.98B at end-2025. CASGEVY revenue was $76M, up 78% QoQ and 151% YoY. The company cited FDA approval for children as young as 2 and began Phase 1 trials for CTX340 and CTX460.
4 min readCRISPR Therapeutics AG (CRSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results ZUG, Switzerland and BOSTON, August 3, 2026 – CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. " The second q
6 min readAccording to Ark Invest, its ARK Innovation ETF (ARKK) increased exposure in late July to space and AI, including about $26M of SpaceX stock, $15.5M of CoreWeave, $14.3M of Tesla, and purchases of Nvidia and TSMC (~$8.2M each) and Meta ($8.6M). Ark reduced Shopify ($12.7M), 10x Genomics ($9.3M) and CRISPR Therapeutics ($6.8M).
3 min readCRISPR Therapeutics (CRSP +1.68%) has had a terrible year, with the stock down 11% as of writing, while the S&P 500 is up 7%. However, the biotech has several catalysts on the horizon, and some analysts are taking notice. Terence Flynn, a Morgan Stanley (MS +3.41%) analyst, recently raised his CRISPR Therapeutics price target to $60, up from $33, and upgraded his rating to "hold." This new target implies the stock could rise by 26% from its current levels.
5 min readThe article lists five biotech stocks for 2026: Vertex (VRTX), Gilead (GILD), Regeneron (REGN), Argenx (ARGX), and CRISPR Therapeutics (CRSP). It cites Vertex revenue guidance of $12.95B to $13.1B and first-quarter revenue of $2,986.9M, plus Argenx full-year revenue of €4.2B and CRISPR’s market cap near $4.58B.
7 min readDelveInsight forecasts the CAR T-cell therapy market for non-Hodgkin lymphoma will grow at about 7% CAGR through 2036, driven by rising relapsed/refractory incidence and broader clinical adoption. It cites pipeline and trial activity for products including Miltenyi’s Zamtocabtagene, Novartis’ Rapcabtagene, Allogene’s Cemacabtagene, and others. Recent updates include FDA approvals for TECARTUS and label changes for YESCARTA, plus early LB2501 results from Legend Biotech.
7 min read
